Citations

Clear

623 citation(s) found for "Torres, V".

Recent Developments in Glioblastoma‐On‐A‐Chip for Advanced Drug Screening Applications
Maity, Surjendu , Bhuyan, Tamanna , Kawakita, Satoru , Sharma, Saurabh , Nguyen, Huu Tuan , Najafabadi, Alireza Hassani , Chen, Junjie , Yilgor, Can , Choroomi, Auveen, Torres, Emily, Mecwan, Marvin , Wang, Zhaohui , Quiñones‐Hinojosa, Alfredo , Jucaud, Vadim , Dokmeci, Mehmet R. , Kawakita, Satoru , Sharma, Saurabh , Nguyen, Huu Tuan , Hassani Najafabadi, Alireza , Khorsandi, Danial , Yilgor, Can , Moniz-Garcia, Diogo, Jucaud, Vadim , Dokmeci, Mehmet Remzi , Khademhosseini, Ali , Jewell, Christopher M. , Ermis, Menekşe , Falcone, Natashya , Mandal, Kalpana , Torres, Emily, John, Johnson V. , Akbari, Mohsen , Moniz‐Garcia, Diogo , Khademhosseini, Ali

Mayo Clinic

Small | November 13, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/smll.202405511 | PMID 39535474 Get It

Abstract Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood‐brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ‐on‐a‐chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM‐on‐a‐chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM‐on‐a‐chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM‐on‐a‐chip models.
BIOM-50. SERIAL INTRACRANIAL CEREBROSPINAL CELL-FREE DNA FOR DISEASE MONITORING IN PATIENTS WITH GLIOMAS
Riviere-Cazaux, Cécile , Dong, Xiaoxi , Mo, Wei , Kumar, Rahul , Andersen, Katherine, Hoplin, Matthew D. , Jusué-Torres, Ignacio , Malik, Noor , Ruff, Michael W. , Uhm, Joon H. , Campian, Jian , Eckel‐Passow, Jeanette E. , Kizilbash, Sani H. , Jia, Shidong , Du, Pan , Warrington, Arthur E. , Kizilbash, Sani H , Jusue-Torres, Ignacio , Malik, Noor , Carlstrom, Lucas P. , Nesvick, Cody L. , Sener, Uğur , Kaufmann, Timothy J. , Routman, David M. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii30-viii31

10.1093/neuonc/noae165.0122 Get It

Abstract Improved response assessment methods are needed for patients with gliomas. Intracranial cerebrospinal fluid (CSF) is longitudinally accessible and provides an abundance source of candidate biomarkers, such as cell-free DNA (cfDNA), for disease monitoring. To evaluate the clinical feasibility of molecular profiling from longitudinal intracranial CSF, CSF was acquired from patients with CSF access devices, including Ommaya reservoirs and ventriculoperitoneal shunts. cfDNA was extracted and analyzed via PredicineCARE (Next Generation sequencing) or PredicineSCORE (low pass whole genome sequencing). Five patients (2 females, 3 males; median age: 40 years, range 32-64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n=4) or VP shunt (n=1). In total, forty-eight CSF samples were obtained (median volume: 4.00 mL; 0.5-5 mL), with 39 samples (81.3%) yielding sufficient cfDNA for variant profiling. Our initial findings suggest that tumor fraction increased by 6.28x, 2.87x, and 8.31x with radiographic progression in three patients. Tumor fraction decreased by 0.08x and 0.04x in two patients with paired immediate pre-versus-post chemoradiation samples. Despite ongoing pseudoprogression in one patient, tumor fraction decreased to unmeasurable levels from a post-resection baseline of 0.26. Patient-specific tumor-associated variant allelic frequencies (VAFs), including TP53, PTEN, TERT, and CDKN2A/B, decreased within individual patients after resection and chemoradiation. In two patients with isocitrate dehydrogenase (IDH) mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate (D-2-HG) levels (0.64x and 0.62x, respectively, for the first patient, and 0.01x and 0.07x for the other patient). Both CSF IDH1 VAF and CSF D-2-HG increased a patient who had radiographic progression (2.56x and 9.21x, respectively). Moreover, CNB decreased below the limit of quantification during treatment and increased above the limit at progression. In conclusion, longitudinal CSF cfDNA can feasibly be obtained via CSF access devices in patients with gliomas during their disease course toward evaluating candidate monitoring biomarkers.
BIOM-52. THE DYNAMIC GLIOMA CSF PROTEOME: IMPACT OF LOCATION AND RESECTION FOR DISEASE MONITORING
Riviere-Cazaux, Cécile , Warrington, Arthur E. , Hoplin, Matthew D. , Andersen, Katherine, Malik, Noor , Jusué-Torres, Ignacio , Meyer, Fredric B. , Kizilbash, Sani H. , Campian, Jian , Parney, Ian, Kizilbash, Sani H , Jusue-Torres, Ignacio , Malik, Noor , Michor, Franziska , Carlstrom, Lucas P. , Ghadimi, Keyvan , Himes, Benjamin , Sarkaria, Jann N. , Gompel, Jamie J. Van , Sener, Uğur , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii31-viii32

10.1093/neuonc/noae165.0124 Get It

Abstract While serial sampling of glioma tissue is rarely performed before recurrence, cerebrospinal fluid (CSF) can be acquired serially to evaluate candidate monitoring and pharmacodynamic biomarkers in patients with gliomas. However, the impact of key variables to consider in longitudinal CSF, including anatomical location and post-surgical changes, remains unknown. To that end, pre- versus post-resection intracranial CSF samples from patients with gliomas were obtained at early (1-16 days; n=20) or delayed (86-153 days; n=11) timepoints, as well as lumbar-versus-intracranial glioma CSF samples (n=14). Using aptamer-based proteomics, we identified significant differences in the glioma CSF proteome between lumbar, subarachnoid, and ventricular CSF. Indeed, intracranial CSF in paired lumbar/intracranial samples had nearly 1600 unique aptamers, regardless of which intracranial location was compared to the paired lumbar CSF, including in enrichment style analyses that evaluated the overlap between protein states. Importantly, resection had a significant, evolving longitudinal impact on the CSF proteome, with subsets of proteins associated with early versus delayed post-resection changes, many of which were enriched for inflammatory-related pathways. Interestingly, despite increased contamination from surgical debris, enrichment for plasma-associated proteins decreased with resection (FDR: 0.000), suggesting that a portion of the baseline glioma panel could be derived from plasma-originating analytes due to blood-brain barrier disruption. Despite these challenges, our data still revealed preliminary candidate monitoring biomarkers, such as brevican, that increased with progression (example patient: fold-change of 3.58x and 2.08x through lomustine and bevacizumab, respectively), but not pseudoprogression (Fold change less than 1.5). Serial intracranial CSF samples suggested the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies, including bevacizumab and pembrolizumab. In conclusion, our available data to date suggest that the intracranial glioma CSF proteome provides an abundant and evolving source of candidate biomarkers to longitudinally discern the impact of resection and systemic treatments.
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials
Leung, Yvette , Vermeire, Séverine , Fellmann, Marc , Modesto, Irene , McDonnell, Aoibhinn , Lazin, Krisztina , Keating, Michael J. , Goetsch, Martina, Wu, Joseph , Vermeire, Séverine , Lees, Charlie W. , Torres, Joana , Loftus, Edward V.

Mayo Clinic

Therapeutic Advances in Gastroenterology | November 8, 2024 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/17562848241293643 | PMID 39526078 Get It

Background: Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). It is known that non-serious treatment-emergent adverse events (TEAEs) may not lead to UC drug discontinuation but can affect treatment tolerability. Objectives: This post hoc analysis evaluated the incidence of specific, common, non-serious TEAEs reported in the etrasimod UC clinical programme and the characteristics of affected patients. Design: Data included patients from the Placebo-controlled UC cohort (phase II OASIS, and phase III ELEVATE UC 52 and ELEVATE UC 12 trials) receiving QD etrasimod (2 or 1 mg) or placebo. Methods: Proportions and incidence rates (IRs; the number of patients with a TEAE divided by the total exposure in patient-years (PYs), per 100 PY) of Headache, Pyrexia, Nausea and Dizziness TEAEs were reported. Changes in heart rate among patients with Dizziness TEAEs were also evaluated. Results: Among 943 patients (etrasimod 2 mg, N = 577 (276.7 PY); etrasimod 1 mg, N = 52 (11.4 PY); placebo, N = 314 (115.1 PY)), 48, 34, 27 and 21 patients experienced events of Headache, Pyrexia, Nausea and Dizziness, respectively. All events were non-serious; one patient treated with etrasimod was discontinued due to a Pyrexia TEAE. Numerically, IRs of Headache and Dizziness TEAEs were higher, and Nausea slightly higher, with etrasimod versus placebo (13.45 vs 8.63 per 100 PY, 6.52 vs 1.69 and 7.18 vs 5.13 per 100 PY, respectively); IRs were similar for Pyrexia. The duration of most TEAEs was 1–10 days. Conclusion: In the etrasimod UC clinical programme, all Headache, Pyrexia, Nausea and Dizziness events were non-serious. Headache and Dizziness were more frequent, and Nausea slightly more frequent, among patients receiving etrasimod versus placebo. The post hoc nature of this analysis is a limitation. These results reiterate the favourable safety profile and tolerability of etrasimod. Trial registration: ClinicalTrials.gov: NCT02447302; NCT03945188; NCT03996369.
Effectiveness of MQ232 in an Orthologous ADPKD Mouse Model
Hu, Jinghua , Gilles, Nicolas, Wang, Xiaofang , Li, Jiang , Gilles, Nicolas , Torres, Vicente E.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024y0pmrggz Get It

Association between Age and Body Mass Index in Patients with End-Stage Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States and Japan
Vaughan, Lisa E. , Madsen, Charles D. , Nishio, Saori , Suwabe, Tatsuya , Torres, Vicente E. , Harris, Peter C. , Hoshino, Junichi

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024r7z84a9x Get It

Characterizing Kidney and Liver Cysts in Monoallelic PKHD1 Individuals Identified in a Population-Based Study
Elbarougy, Doaa E. , Jawaid, Tabinda , Yang, Hana , Frank, Jacob A., Ma, Jun , Gregory, Adriana , Kline, Timothy L. , Elbarougy, Doaa E , McDonnell, Shannon K. , Torres, Vicente E. , Chebib, Fouad T. , Hanna, Christian , Larson, Nicholas B. , Harris, Peter C.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024fg7ej691 Get It

Kidney Stone Incidence in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Ostrow, Anna, Gregory, Adriana , Kline, Timothy L. , Dahl, Neera K. , Chonchol, Michel , Dahl, Neera K , Harris, Peter C. , Erickson, Bradley J. , Nowak, Kristen L. , Torres, Vicente E. , Goldfarb, David S. , Gitomer, Berenice Y

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024nvt3dy6d Get It

Automated Segmentation of Individual Kidney Cysts in Routine Abdominal CT Images
Gregory, Adriana , Im, J G, Khalifa, Muhammed, Kline, Timothy L. , Im, Jeeho, Khalifa, Muhammed, Chebib, Fouad T. , Torres, Vicente E. , Harris, Peter C. , Erickson, Bradley J.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024jwnbw7p8 Get It